Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus camrelizumab for advanced thyroid cancer
ChiCTR2100048908Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and camrelizumab in thyroid cancer, well-differentiated thyroid cancer (WDTC), Medullary Thyroid Cancer (MTC) and 1 more, sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)Medullary Thyroid Cancer (MTC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on ChiCTR2100048908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048908.